Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

NCT05351593 is registered in ClinicalTrials.gov with James Rubenstein as lead sponsor.

NCT NCT05351593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Lead sponsor
James Rubenstein
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 8, 2022
Completion date
September 30, 2027
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cns lymphoma, primary central nervous system lymphoma, secondary central nervous system lymphoma